argenex (NASDAQ:ARGX) Posts Quarterly Earnings Results, Beats Expectations By $1.46 EPS

argenex (NASDAQ:ARGX) released its quarterly earnings results on Tuesday. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46, Zacks reports. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 31.31% and a return on equity of 44.37%.

argenex Stock Up 6.8%

NASDAQ:ARGX traded up $57.76 during trading hours on Thursday, reaching $909.48. 454,040 shares of the company’s stock were exchanged, compared to its average volume of 353,501. argenex has a 12 month low of $577.04 and a 12 month high of $953.58. The company has a market capitalization of $56.90 billion, a P/E ratio of 40.50, a price-to-earnings-growth ratio of 1.08 and a beta of 0.45. The business’s 50-day simple moving average is $863.85 and its two-hundred day simple moving average is $813.80.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Weiss Ratings raised argenex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 6th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. HC Wainwright restated a “buy” rating and set a $940.00 price objective on shares of argenex in a research report on Thursday, June 25th. Royal Bank Of Canada lifted their target price on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Morgan Stanley increased their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,042.67.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. acquired a new position in argenex during the third quarter worth $36,000. Geneos Wealth Management Inc. lifted its position in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the last quarter. Transamerica Financial Advisors LLC increased its position in argenex by 80.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 85 shares of the company’s stock worth $71,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in argenex by 113.1% during the 2nd quarter. Rakuten Securities Inc. now owns 130 shares of the company’s stock valued at $72,000 after purchasing an additional 69 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported second-quarter 2026 earnings that beat expectations, with EPS of $7.32 versus consensus of $5.86 and revenue of $1.54 billion versus estimates of $1.45 billion, reinforcing solid execution. Article Title
• Positive Sentiment: Management said Vyvgart sales jumped about 60% year over year, a key growth driver that supports the company’s near-term revenue momentum ahead of upcoming pipeline readouts. Article Title
• Positive Sentiment: Several analyst notes were constructive, including Guggenheim reiterating a Buy and Citigroup raising its price target, signaling confidence in further upside after the earnings update. Article Title Article Title
• Neutral Sentiment: argenx also released its half-year 2026 financial results and second-quarter business update, which investors are likely parsing for pipeline progress and launch trends. Article Title

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.